Aim:CT-guided stereotactic brain biopsy has been performed in our clinic since March 1998. In this prospective study, we examined the patient data undergoing stereotactic biopsy and the results of biopsies in consecutive 500 patients.Material and Methods:: Between the dates of March 1998 and January 2015, CT guided stereotactic biopsies were performed by using the Leksell stereotactic frame system (Elekta Instruments EU, Sweden) in 500 patients. A total of 512 procedures were performed in patients consisting of 184 females (36.8%) and 316 males (63.2%), ages ranging from 3 to 81 (mean 50.40±16.67).Results:Conclusive histopathological diagnosis was not achieved in 17(3.3%) of 512 procedures. Of the others, 173 (33.8%) were high grade gliomas, 103 (20.1%) were low grade gliomas, 36 (7%) were malign lymphomas, 34 (6.6%) were other type of brain tumors, 82 (16%) were metastasis and 67 (13.1%) were non tumoral lesions. Complications were occurred in ten cases: 3 tumoral bleeding, 2 hypertensive cerebral hematoma, 2 peroperative convulsion, 1 epidural hematoma, 1 myocard infarction and 1 brain edema. The patients who developed myocard infarction and hypertensive thalamic hematoma died. The mortality was 0.4% and morbidity was 1.6% in 512 procedures... Conclusion:Our data reveals that CT-guided stereotactic biopsy is a reliable and a safe procedure in cases with intracranial lesions when histopathological diagnosis is required for the appropriate treatment.